Filippo Menolascina uses Co-Scientist to identify novel drug combinations and help researchers understand why approved treatments like resmetirom only benefit certain patients.

DM provides a diverse range of content spanning technology, business, and culture, offering articles, interviews, and analysis for readers interested in staying updated with the latest trends and developments across various industries. Readers can learn about emerging technologies, industry insights, and  perspectives from experts in different fields.

DeepMind

Google DeepMind's Co-Scientist AI tool is being used by researchers at the University of Edinburgh to accelerate liver disease research. Bioengineer Filippo Menolascina applied it to metabolic dysfunction-associated steatohepatitis (MASH), a complex liver disease requiring combination therapies. Co-Scientist synthesized biomedical literature to identify overlooked mechanisms and candidate drug combinations. In a key case, it generated a novel hypothesis linking the NLRP3 inflammasome as a molecular bridge between inflammation and metabolism — explaining why the drug resmetirom only helps a subset of eligible patients. This hypothesis was subsequently verified experimentally, potentially opening the door to targeted dual-therapies.